Australian researchers have uncovered a critical mechanism driving the growth and spread of glioblastoma—one of the most ...

The name might sound like a Nordic god, but it is actually the molecular machinery that allows many different species to eat ...

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its audited financial results ...

Arch Biopartners announces SM begins patient dosing in phase II CS-AKI trial of LSALT peptide: Toronto Monday, March 23, 2026, 18:00 Hrs [IST] Arch Biopartners Inc. (Arch) announc ...

Explore cancer drug resistance and its significant impact on treatment options and patient outcomes in modern cancer therapy.

Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first ...

On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end of this month - - GLIX1 is positioned to potentially address unmet ...

Highlighting Positive Results in Comparison to Valchlor(R) and in Real-World Use PRINCETON, N.J., March 23, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage ...

Highlighting Positive Results in Comparison to Valchlor® and in Real-World Use PRINCETON, N.J., March 23, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: ...

Several experimental prostate cancer drugs have produced striking results in early-stage clinical trials, with at least one ...

Breast cancer remains one of the most prevalent malignancies worldwide, with approximately 2.3 million new cases diagnosed annually. Cytokines - small ...

Having moved beyond its defining role in the COVID-19 pandemic, BioNTech now faces a critical juncture. The company's future ...